Introduction {#S6}
============

In a 2010 report by the World Health Organization, non-communicable diseases including cardiovascular diseases, diabetes, cancers, and chronic respiratory diseases, accounted for nearly two-thirds of deaths worldwide and this chronic disease burden largely results from obesity both directly and indirectly. In the United State, the proportion of the population that is obese has increased gradually over time. The age-adjusted prevalence of obesity in adults increased from 30.5% to 35.7% between 1999 and 2010 and over the same time period, the prevalence of diabetes also increased from 9.0% to 11.5%.^[@R1]^

It has been suggested that disease risk associated with obesity may not be uniform and that a subgroup of obese individuals, referred to as metabolically healthy but obese (MHO), appears resistant to metabolic and cardiovascular risk from obesity.^[@R2]--[@R5]^ An important issue, however, is that all of the criteria for MHO that have been used in the reported literature do not exclude all of the variables associated with the metabolic syndrome. Thus, the prevalence of MHO has been reported to vary between 10% and 40% depending upon the definition used and is higher in the non-Hispanic white populations, younger individuals, and women.^[@R6]^ However, it has also been suggested that healthy obesity is a transient state with one-third of such subjects developing metabolic abnormalities or diabetes in the future.^[@R7]^ In addition, a recent meta-analysis that included prospective studies with at least 10-years of follow-up showed that MHO individuals had a 1.24-fold higher risk for all-cause mortality and/or cardiovascular events compared with metabolically healthy normal-weight individuals. Therefore, the authors concluded that greater body mass index (BMI) conveys additional health risks even in the absence of metabolic abnormalities, thereby challenging the concept of MHO.^[@R8]^

To date, however, little is known about the natural history of MHO and predictors of future conversion to metabolically unhealthy obese (MUO) phenotype. Thus, the aims of this study were to determine how frequently MHO converts to MUO, and which demographic, lifestyle, clinical, and metabolic variables predict this conversion, with a particular focus on the roles of visceral abdominal fat (VAT) and subcutaneous abdominal fat (SAT) directly measured by computed tomography (CT).

Methods {#S7}
=======

Study subjects {#S8}
--------------

The study population consisted of Japanese American men and women enrolled in the Japanese American Community Diabetes Study, a cohort of second- (Nisei) and third-generation (Sansei) Japanese Americans of 100% Japanese ancestry. A detailed description of the selection and recruitment of the study subjects has been published previously.^[@R9],[@R10]^ In brief, study participants were selected as volunteers from a community-wide comprehensive mailing list and telephone directory that included nearly 95% of the Japanese-American population in King County, Washington. Among the total of 658 subjects in the original cohort, 384 non-obese subjects were excluded. Six subjects were excluded because data for defining metabolic health status were not available at baseline, leaving 271 obese subjects for analysis. Among these 271 obese subjects, 97 (35.7%) showed the MHO phenotype at baseline and over 10 years, 85 with MHO (56 men and 29 women), aged 34--73 years (mean age of 49.8 years), had sufficient follow-up data for this analysis. Subjects were followed up at 2.5 years (Nisei men only), 5 years and 10 years after a baseline examination to determine metabolic status and clinical and biochemical variables of interest.

The study received approval from the University of Washington Human Subjects Division, and written informed consent was obtained from all subjects.

Clinical and laboratory examination {#S9}
-----------------------------------

All evaluations were performed at the General Clinical Research Center, University of Washington. At baseline, a complete physical examination was performed, and personal medical history and lifestyle factors were determined using a standardized questionnaire. Smoking was classified into three groups (current smoker, past smoker, and never smoker). Excessive alcohol intake was defined as more than three drinks per day (\>30 g ethanol/day). Paffenbarger physical activity index questionnaire was used to determine physical activity level (usual kilocalories spent weekly)^[@R11]^ and regular physical activity was defined as more than moderate intensity physical activity. The collection of dietary data followed a format adapted from the Burke diet-history method including 1) a food frequency questionnaire (FFQ), 2) background information, and 3) a 24-h recall of dietary intake.^[@R12]^

Body mass index (BMI) was calculated as weight in kilograms divided by the square of the height in meters. Waist circumference was measured at the level of the umbilicus. Blood pressure was measured with a mercury sphygmomanometer read to the nearest 2 mmHg with the subjects in a recumbent position. Systolic blood pressure was determined by the first perception of sound and diastolic blood pressure was determined at the disappearance of sounds (fifth-phase Korotkoff). Average blood pressure was calculated from the second and third of three consecutive measurements.

Biochemical measurements were performed as reported previously.^[@R13]^ All blood samples were obtained following an overnight fast of 10 hours. Plasma glucose was measured by the hexokinase method using an autoanalyzer (University of Washington, Department of Laboratory Medicine, Seattle, WA). Plasma insulin was measured by radioimmunoassay (Immunoassay Core, Diabetes Endocrinology Research Center, University of Washington, Seattle, WA). To estimate insulin sensitivity, the homeostasis model assessment (HOMA) insulin resistance based on fasting glucose and insulin concentration was used.^[@R14]^ Lipids and lipoproteins measurements were performed according to modified procedures of the Lipid Research Clinics (Northwest Lipid Research Laboratory, University of Washington, Seattle, WA). Single 10 mm slice CT scans were performed at the abdomen, and right mid-thigh to measure cross-sectional fat areas (cm^2^) as described previously.^[@R15]^ VAT and SAT areas were measured at the umbilicus level. Attenuation range for identification of fat was -250 to -50 Hounsfield Units.

Definition of MHO {#S10}
-----------------

'Metabolic health' was defined using the criteria proposed by the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) for the diagnosis of metabolic syndrome with minor modification^[@R16]^: (1) the presence of central obesity (waist circumference ≥90 cm in men and ≥80 cm in women). This cutoff for central obesity was adopted from the International Diabetes Federation (IDF) definition for Asian populations^[@R17]^; (2) triglyceride levels ≥150 mg/dL; (3) HDL cholesterol \<40 mg/dL in men and \<50 mg/dL in women, (4) systolic or diastolic blood pressure ≥130/85 mmHg or use of antihypertensive medications, or (5) fasting plasma glucose ≥100 mg/dL or 2 hour glucose after oral glucose tolerance test ≥140 mg/dL or use of oral hypoglycemic agents and/or insulin. Obesity was defined as BMI of ≥25 kg/m^2^ using the cut-point for Asian populations as recommended by the World Health Organization.^[@R18]^ According to these criteria, and since no standard definition of MHO exists, we used one commonly used definitions of MHO, namely the presence of two or fewer of the above five metabolic syndrome components plus BMI ≥25.0 kg/m^2^. MUO was defined as the presence of three or more of aforementioned metabolic syndrome components plus BMI ≥25.0 kg/m^2^.

Statistical analyses {#S11}
--------------------

Data are expressed as means ± SD for continuous measures except for skewed continuous variables, which are presented as the median (interquartile range, 25--75%) or as proportions for categorical variables. Differences between groups were tested by the student *t*-test or Mann-Whitney U test for continuous variables and the χ^2^-test or Fischer's exact test for categorical variables. Multiple logistic regression analysis with backward selection was used to determine independent associations between clinical and biochemical variables and future conversion to MUO as a binary variable. Odds ratios (ORs) with 95% confidence intervals (CI) were calculated for independent variables included in logistic models, with a 1-SD increment used for odds ratio calculations for continuous measurements. We assessed the presence of nonlinearity in the final model by inserting quadratic transformations of the three continuous variables that it contained into the model. The presence of interaction was tested in multivariate models by testing the significance of first order interaction terms. All statistical analyses were performed using PASW version 18.0 (SPSS, Chicago, IL, USA). A *P*-value of \<0.05 was considered significant.

Results {#S12}
=======

Over 10 years of follow-up, almost two-thirds of subjects with the MHO phenotype (64.7%, 55/85) developed MUO. [Table 1](#T1){ref-type="table"} shows the baseline characteristics of study participants by MHO or MUO phenotype at the 10 year follow-up. There were no differences in age, sex, menopause in women, dietary intake including daily energy intake and macronutrient composition and lifestyle factors including alcohol consumption, smoking, and physical activity between the MHO and MUO subjects. In addition, no differences were noted in fasting and 2-hour plasma glucose levels and blood pressure between the two groups. However, subjects with future conversion to MUO had significantly lower HDL cholesterol and higher triglyceride levels and showed greater insulin-resistance (as reflected by fasting insulin levels and HOMA-IR) compared with subjects in whom MHO persisted throughout follow-up. In terms of body composition, baseline SAT and VAT areas were significantly and positively associated with the development of MUO over follow-up; however, no significant differences were observed in baseline BMI, waist circumference, VAT to SAT ratio, or subcutaneous thigh fat area between the two groups.

Similarly, in univariate logistic regression analysis, fasting plasma insulin, HOMA-IR, and triglyceride showed positive associations with the development of MUO while HDL cholesterol was inversely associated with this outcome. Regarding body fat compartments, SAT (OR per 1-SD increment (95% CI), 1.81 (1.08 -- 3.02), *P*=0.024) and VAT (OR per 1-SD increment (95% CI), 1.99 (1.17 -- 3.39), *P*=0.011) were associated with future conversion to MUO in subjects with baseline MHO; however, VAT to SAT ratio and subcutaneous thigh fat were not ([Table 2](#T2){ref-type="table"}).

To determine which variables independently predicted future conversion to MUO, a backwards selection logistic regression model was fit that included age and sex as well as variables found significantly related to the MUO outcome in univariate analysis from [Table 2](#T2){ref-type="table"} (HDL cholesterol, triglyceride, fasting insulin, SAT, and VAT). Since fasting insulin and HOMA-IR are highly correlated, the former only was chosen for inclusion in the backwards selection model due to its smaller p-value in univariate analysis ([Table 2](#T2){ref-type="table"}). In the final model, HDL cholesterol (OR per 1 SD increment (95% CI), 0.24 (0.11 -- 0.53), *P*\<0.001), female sex (OR per 1 SD increment (95% CI), 5.37 (1.14 -- 25.27), *P*=0.033), fasting plasma insulin (OR per 1 SD increment (95% CI), 2.45 (1.07 -- 5.62), *P*=0.034), and VAT (OR per 1 SD increment (95% CI), 2.04 (1.11 -- 3.72), *P*=0.021) were associated with the risk of future MUO. However, SAT was not independently associated with future conversion to MUO ([Table 3](#T3){ref-type="table"}). No significant interactions were observed between sex and each of the independent variables shown in the model in [Table 3](#T3){ref-type="table"} in predicting the occurrence of MUO. Quadratic transformations of HDL cholesterol, VAT and fasting plasma insulin were inserted into the final model. None of these was statistically significant, arguing against a nonlinear association between any of these continuous predictors and risk of conversion to MUO.

Discussion {#S13}
==========

In the current prospective study of Japanese American men and women with BMI of ≥25 kg/m^2^, approximately one-third (35.7%, 97/271) showed the MHO phenotype at baseline. However, almost two-thirds of the subjects with MHO (64.7%, 55/85) deteriorated to the MUO phenotype during 10 years of follow-up. In particular, greater VAT at baseline was independently associated with future metabolic deterioration to MUO in subjects with MHO; however, other measurements of body fat such as baseline BMI and waist circumference in univariate analysis, and SAT in a multivariate model did not confer any significant alteration in risk for future conversion to MUO.

There has been much debate about whether MHO is a totally benign condition or is associated with future disease burden. In the Framingham Offspring Study in the U.S., obese individuals with metabolic syndrome or insulin resistance showed greater risk for diabetes and cardiovascular disease compared with obese subjects without metabolic syndrome or insulin resistance. In addition, MHO subjects had lower risk for cardiovascular disease similar to normal weight subjects without insulin resistance.^[@R19]^ Another community-based prospective observational study in Scotland and England also suggested that MHO subjects had similar risk for future cardiovascular and all-cause mortality compared to metabolically healthy nonobese subjects over 7 years. Moreover, the same result was observed even when lean subjects (BMI \<25 kg/m^2^) without any metabolic risk factors were used as the reference group. Metabolically unhealthy nonobese subjects showed a higher cardiovascular and all-cause mortality compared with metabolically healthy nonobese subjects. Thus, the authors suggested that metabolic risk factors are more important for future disease burden than adiposity itself.^[@R20]^ However, accumulating evidence does not support the concept that MHO is a sustained benign condition.^[@R7],[@R21]--[@R24]^ In a meta-analysis of eight prospective cohort studies, although MHO subjects had lower risk for incident type 2 diabetes compared with MUO subjects, this subgroup showed over four times greater risk compared with healthy normal weight adults.^[@R25]^ Another meta-analysis of eight prospective observational studies showed that MHO subjects have a higher risk for all-cause mortality and cardiovascular events than metabolically healthy normal weight individuals, and that all subjects with unhealthy metabolic phenotype have a higher risk regardless of BMI. Therefore, the authors concluded that comprehensive evaluation of both adiposity and metabolic factors are necessary to predict future morbidity and mortality.^[@R8]^

In support of the finding that MHO is not a benign condition, recent studies suggested that MHO is transient and may change into an unhealthy phenotype over time.^[@R7],[@R23]^ In the prospective Pizarra study in Spain, more than 30% of MHO subjects at baseline became metabolically unhealthy by the 6-year follow-up and were at a significantly higher risk for the development of diabetes over time.^[@R23]^ In addition, the North West Adelaide Health Study in Australia showed that approximately one-third of MHO subjects at baseline converted into the metabolically unhealthy phenotype during 5.5--10.3 years of follow-up, with lower risk for incident type 2 diabetes evident only in subjects with sustained MHO.^[@R7]^ In partial agreement with these studies, MHO subjects in our study converted to an unhealthy phenotype over time; however, our results showed a higher conversion rate (64.7%) to MUO phenotype than in previous studies. We speculate that our longer follow up period (10 years) than the aforementioned two studies may explain these differences. The proportion of our subjects who converted to MUO was somewhat lower at 5 year (43.5%, 37/85) than 10 year follow-up. In addition, several different criteria have been used to define MHO in the reported studies as well as ethnic differences in study subjects may explain these different results. Several definitions are currently used to describe metabolic health and there is no unifying established MHO definition. In addition, different inclusion criteria and/or cut-offs have been used to discriminate metabolically healthy from metabolically unhealthy subjects. For example, not all metabolic health definitions include insulin resistance (defined by HOMA-IR), blood pressure or fasting plasma glucose concentrations, while others consider inflammatory markers.^[@R5]^

Despite accumulating evidence suggesting that MHO is not a static condition, little attention has been given regarding the variables that predict metabolic deterioration to MUO in MHO subjects. To our knowledge only cross-sectional analyses have been published that compare baseline characteristics between subjects with MHO and MUO. Previous studies have suggested that MHO subjects were more likely to be younger, female, and of non-Hispanic white ethnicity than subjects with MUO.^[@R6]^ In addition, MHO subjects showed greater insulin sensitivity and higher adiponectin level than MUO subjects.^[@R2]^ In terms of body composition, most studies have shown that MHO subjects have smaller VAT than MUO subjects; however, no difference was previously observed in SAT between the two groups.^[@R26],[@R27]^ In contrast, our analysis demonstrated that although baseline BMI and waist circumference were similar between the two groups, both SAT and VAT were greater in subjects with future conversion to MUO. In addition, although it was suggested that a greater amount of subcutaneous thigh fat is associated with favorable metabolic phenotype,^[@R26],[@R28]^ our results did not show any protective effect of subcutaneous thigh fat against future conversion to MUO. The discrepancies in body composition and conversion to MUO between previous studies and our results appear to be mainly from the longitudinal nature of our research and different criteria used to define MHO. In addition to the 10 year result, we determined which variables independently predict future conversion to MUO in subjects with MHO at an earlier 5 year time point. In this analysis, HDL cholesterol (OR per 1 SD increment (95% CI), 0.37 (0.19 -- 0.71), *P*=0.003) was inversely associated and SAT (OR per 1 SD increment (95% CI), 2.39 (1.33 -- 4.31), *P*=0.004) and VAT (OR per 1 SD increment (95% CI), 2.07 (1.19 -- 3.58), *P*=0.010) were positively associated with the risk of future MUO (data not shown). Therefore, the 5 year and 10 year results suggest that although the association between SAT and the conversion of MHO to MUO is seen in the short term, SAT is not a sustainable long-term predictor for this conversion whereas VAT is consistently associated with the conversion to MUO in subjects with MHO at both 5 and 10 years of follow-up.

In the current study, we compared daily energy intake and composition of macronutrients between subjects who remained in MHO and subjects with converted to MUO. However, there were no differences in daily energy intake and percentage of calories from each macronutrient between the two groups. In addition, no difference was noted in physical activity between the two groups. Therefore, it appears that energy intake and expenditure were not major determinants for conversion to a metabolically unhealthy phenotype in subjects with MHO in our study cohort.

It is still uncertain whether MHO is related to sex. Some studies demonstrated that MHO was more common in women^[@R24],[@R29]^ while others showed no difference by sex.^[@R2],[@R27]^ In contrast, our result indicated that female sex independently predicts future conversion to MUO in subjects with MHO. Although the proportion of MHO among obese subjects is higher in women in some studies but not all, our study found that female sex predicts progression to a MUO phenotype among MHO subjects. In our study, we defined MHO based on the NCEP-ATP III criteria for metabolic syndrome and it has been well-documented that the prevalence of the metabolic syndrome by this definition is higher in men than women at younger ages, but becomes similar or even higher in women over 50 years of age.^[@R30]^ Of note, the mean age was 61.9 years in our female subjects at the follow-up examination.

This study has some limitations. First, the small sample size may have limited our ability to detect weaker associations and prevented us from performing sub-group analyses, e.g., by gender. However, no significant interactions were observed between sex and other variables that remained in the multivariate model. Thus, our results appear to be applicable to both men and women. Second, it was reported that Asians have a relatively larger amount of abdominal fat, and that this difference was more evident in VAT compared with Caucasians.^[@R31]^ Therefore, our findings may not be generalizable to other ethnic groups if the association between VAT and other body fat depots and future conversion to MUO varies with ethnicity. Third, recent studies have suggested that SAT is further separable into two distinct subdepots: the superficial SAT and the deep SAT and that they have distinct histological and physiological features and furthermore display different associations with cardiometabolic variables.^[@R32]^ However, we did not measure regional SAT in this study. Fourth, we did not account for hard endpoints arising from metabolically healthy or unhealthy status such as cardiovascular disease or mortality.

Despite these limitations, this study found that MHO is a transient state and that a high proportion of this unique subgroup deteriorates metabolically over time. In addition, we believe that we have prospectively examined for the first time the roles of different body fat compartments with the development of future MUO phenotype among persons with MHO and showed VAT is the main body fat depot in predicting conversion to MUO in subjects with MHO. These results argue that clinical providers should not view MHO as a benign form of obesity and be complacent regarding their patients who have excess body weight but few metabolic abnormalities. In addition, because baseline BMI and waist circumference have limited value in predicting the conversion from MHO to MUO, the measurement of VAT may be a potential option to predict future metabolic deterioration in subjects with MHO.
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###### 

Baseline characteristics according to metabolic status after 10 years

                                                 Total (n=85)             MHO at follow-up (n=30)   MUO at follow-up (n=55)   *P*
  ---------------------------------------------- ------------------------ ------------------------- ------------------------- -------
  Age (years)                                    49.8 (12.0)              48.9 (11.0)               50.2 (12.6)               0.63
  Female sex (%)                                 29 (34.1)                7 (23.3)                  22 (40.0)                 0.12
  Menopause in women (%)                         16 (55.2)                4 (57.1)                  12 (54.5)                 1.00
  Body mass index (kg/m^2^)                      27.0 (1.8)               26.6 (1.7)                27.2 (1.8)                0.12
  Waist circumference (cm)                       88.9 (6.4)               87.8 (5.0)                89.5 (7.0)                0.20
  Alcohol consumption (%)                        5 (5.9)                  3 (10.0)                  2 (3.6)                   0.34
  Current smoking (%)                            10 (11.8)                1 (3.3)                   9 (16.4)                  0.09
  Regular physical activity (%)                  23 (27.1)                11 (36.7)                 12 (21.8)                 0.12
  Daily energy intake (kcal/day)                 1901.2 (627.5)           1976.4 (733.4)            1860.1 (564.6)            0.42
  Calories from carbohydrate (%)                 47.3 (7.4)               46.7 (7.1)                47.6 (7.6)                0.58
  Calories from fat (%)                          32.4 (5.5)               31.8 (6.2)                32.7 (5.1)                0.44
  Calories from protein (%)                      18.5 (3.7)               18.9 (3.2)                18.3 (4.0)                0.50
  Systolic blood pressure (mmHg)                 125.5 (12.7)             124.5 (13.6)              126.1 (12.3)              0.59
  Diastolic blood pressure (mmHg)                75.4 (7.5)               76.0 (8.8)                75.1 (6.8)                0.59
  Fasting plasma glucose (mmol/L)                5.33 (0.96)              5.22 (0.82)               5.39 (1.02)               0.44
  2 hour plasma glucose (mmol/L)                 7.66 (2.83)              7.18 (2.61)               7.92 (2.94)               0.25
  Fasting plasma insulin (pmol/L)                83.3 (69.5 -- 125.0)     79.9 (61.1 -- 92.4)       97.2 (76.4 -- 142.4)      0.001
  HOMA-IR                                        2.92 (2.25 -- 4.35)      2.45 (1.86 -- 3.11)       3.36 (2.52 -- 4.86)       0.002
  Total cholesterol (mmol/L)                     5.79 (1.04)              5.74 (1.02)               5.82 (1.06)               0.73
  HDL cholesterol (mmol/L)                       1.42 (0.30)              1.56 (0.31)               1.34 (0.26)               0.001
  Triglycerides (mmol/L)                         1.30 (0.99 -- 1.48)      1.16 (0.72 -- 1.45)       1.38 (1.12 -- 1.63)       0.014
  LDL cholesterol (mmol/L)                       3.78 (0.93)              3.69 (0.90)               3.83 (0.95)               0.50
  Subcutaneous abdominal fat (cm^2^)             185.9 (136.1 -- 243.0)   157.9 (128.3 -- 206.4)    210.1 (143.5 -- 263.2)    0.012
  Visceral abdominal fat (cm^2^)                 89.5 (68.8 -- 121.9)     76.3 (45.6 -- 98.8)       101.1 (78.3 -- 138.5)     0.005
  Visceral to subcutaneous abdominal fat ratio   0.46 (0.32 -- 0.64)      0.45 (0.30 -- 0.66)       0.49 (0.33 -- 0.63)       0.49
  Subcutaneous thigh fat (cm^2^)                 62.6 (43.0 -- 91.9)      61.5 (43.8 -- 90.3)       64.6 (42.4 -- 92.2)       0.95

Data are expressed as mean (SD), median (inter-quartile range), or frequency (%). MHO, metabolically heathy obese; MUO, metabolically unhealthy obese

###### 

Univariate logistic regression analysis for the metabolic abnormalities after 10 years

                                                 OR (95% CI)[\*](#TFN2){ref-type="table-fn"}   *P*
  ---------------------------------------------- --------------------------------------------- -------
  Age                                            1.12 (0.72 -- 1.75)                           0.63
  Female sex                                     2.19 (0.80 -- 5.98)                           0.13
  Body mass index                                1.50 (0.90 -- 2.49)                           0.12
  Waist circumference                            1.31 (0.83 -- 2.07)                           0.24
  Alcohol consumption                            0.34 (0.05 -- 2.16)                           0.25
  Current smoking                                5.67 (0.68 -- 47.16)                          0.11
  Regular physical activity                      0.54 (0.20 -- 1.41)                           0.21
  Systolic blood pressure                        1.13 (0.72 -- 1.78)                           0.59
  Diastolic blood pressure                       0.88 (0.55 -- 1.40)                           0.59
  Fasting plasma glucose                         1.23 (0.73 -- 2.09)                           0.44
  2 hour plasma glucose                          1.37 (0.80 -- 2.33)                           0.25
  Fasting plasma insulin                         3.21 (1.51 -- 6.82)                           0.002
  HOMA-IR                                        3.02 (1.38 -- 6.59)                           0.006
  Total cholesterol                              1.09 (0.69 -- 1.71)                           0.73
  HDL cholesterol                                0.42 (0.24 -- 0.74)                           0.002
  Triglycerides                                  2.01 (1.13 -- 3.59)                           0.018
  LDL cholesterol                                1.17 (0.74 -- 1.85)                           0.49
  Subcutaneous abdominal fat                     1.81 (1.08 -- 3.02)                           0.024
  Visceral abdominal fat                         1.99 (1.17 -- 3.39)                           0.011
  Visceral to subcutaneous abdominal fat ratio   1.27 (0.73 -- 2.22)                           0.39
  Subcutaneous thigh fat                         1.12 (0.71 -- 1.77)                           0.63

Odds ratios for continuous variables are shown for a 1-SD increment.

###### 

Multivariate logistic regression analysis with backward selection for the development of metabolic abnormalities after 10 years

                           OR (95% CI)[\*](#TFN4){ref-type="table-fn"}   *P*
  ------------------------ --------------------------------------------- ---------
  Female sex               5.37 (1.14 -- 25.27)                          0.033
  HDL cholesterol          0.24 (0.11 -- 0.53)                           \<0.001
  Fasting plasma insulin   2.45 (1.07 -- 5.62)                           0.034
  Visceral abdominal fat   2.04 (1.11 -- 3.72)                           0.021

Age, sex, HDL cholesterol, triglyceride, fasting plasma insulin, subcutaneous abdominal fat, and visceral abdominal fat were initially included in this model. A backwards elimination algorithm led to the final model shown.

Odds ratios for continuous variables are shown for a 1-SD increment.

[^1]: Deceased
